Investigating how abnormal signaling in brain tumors affects immune response in glioblastoma
Aberrant activation of epidermal growth factor receptor signaling drives programming of an immunosuppressive brain tumor microenvironment in glioblastoma
This study is looking at how a specific protein called EGFR makes it harder for the immune system to fight glioblastoma, a tough type of brain tumor, and it hopes to find new ways to boost the immune response to help patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10998458 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, the most common and aggressive brain tumor, which often resists effective treatments. The study aims to understand how abnormal activation of the epidermal growth factor receptor (EGFR) contributes to an immunosuppressive environment in the brain, hindering the body's ability to fight the tumor. By using advanced models, the researchers will explore whether targeting EGFR can enhance immune responses against glioblastoma. This could lead to new therapeutic strategies that improve outcomes for patients suffering from this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel immunotherapy approaches.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the immune system's ability to combat glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting EGFR in other cancers, but this specific approach in glioblastoma is relatively novel and untested.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Pioso, Marissa S — University of California Los Angeles
- Study coordinator: Pioso, Marissa S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.